Gemcitabine-induced peripheral vascular disease and prolonged response in a patient with metastatic pancreatic adenocarcinoma:A case report  

作　　者：Moinard-Butot Fabien Poprawa Elodie Schohn Anna Pietro Addeo Benabdelghani Meher 

机构地区：[1]Department of Medical Oncology,Institut de Cancérologie Strasbourg Europe,Strasbourg 67200,France [2]Department of Supportive Care,Institut de cancérologie Strasbourg Europe,Strasbourg 67200,France [3]Hepato-Pancreato-Biliary Surgery and Liver Transplantation,Hôpitaux Universitaires de Strasbourg,Strasbourg 67200,France

出　　处：《World Journal of Clinical Cases》2023年第6期1372-1378,共7页世界临床病例杂志

摘　　要：BACKGROUND Gemcitabine is an antimetabolite used in the treatment of pancreatic cancer.One of the side effects of gemcitabine is vascular toxicity.Here,we report the case of a patient treated with gemcitabine who had peripheral vascular disease concomi-tant with a prolonged antitumor response.CASE SUMMARY A 75-year-old man was diagnosed with locally recurrent pancreatic cancer.Partial response was achieved after 9 mo of gemcitabine.At the same time,the patient reported peripheral vascular disease without necrosis.Chemotherapy was suspended,and after one month the Positron Emission Tomography(PET)scan showed locoregional tumor recurrence.Gemcitabine was resumed and partial response was obtained,but peripheral vascular disease occurred.CONCLUSION Our results suggest that the appearance of peripheral vascular disease may be related to a prolonged response to gemcitabine.

关 键 词：GEMCITABINE Pancreatic cancer Peripheral vascular disease Prolonged tumor response Case report 

分 类 号：R735.9[医药卫生—肿瘤]